Participation of clinical pharmacists in patient with extreme thrombocytosis induced by piperacillin sodium and tazobactam sodium injection
10.12206/j.issn.2097-2024.202601008
- VernacularTitle:临床药师参与注射用哌拉西林钠他唑巴坦钠致极重度血小板增多的病例分析
- Author:
Xia LI
1
;
Yue SUN
1
;
Xiaofei FU
2
Author Information
1. Clinical Pharmacy Department, Yumen General Hospital/Yumen First People's Hospital, Yumen 735211, China.
2. Department of Pharmacy, Rocket Force Characteristic Medical Center, Beijing 100088, China.
- Publication Type:Medicine&Clinical
- Keywords:
piperacillin sodium and tazobactam sodium injection;
thrombocytosis;
adverse drug reaction;
pharmaceutical care
- From:
Journal of Pharmaceutical Practice and Service
2026;44(5):268-271
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical characteristics and risk factors of extreme thrombocytosis caused by piperacillin sodium and tazobactam sodium injection, and provide reference for medical treatment and pharmaceutical care of such patients. Methods Extreme thrombocytosis of a patient treated with piperacillin sodium and tazobactam sodium injection was found by clinical pharmacists, who participated in clinical diagnosis and treatment by analyzing of the adverse drug reaction, optimization of the medical treatment and pharmaceutical care. Results After correlation analysis, the patient's extreme thrombocytosis was likely to be an adverse reaction caused by the piperacillin sodium and tazobactam sodium injection. The medication was immediately discontinued, and antiplatelet therapy with aspirin was administered. Two weeks later, the patient's platelet count had significantly decreased compared to before. Conclusion Clinical pharmacists participated in patients’ clinical diagnosis and treatment, carried out pharmaceutical care and assisted physicians in adjusting treatment plans, which ensured the safety and effectiveness of patients' clinical drug therapy.
